NCT01466062

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 24 Months
• Healthy volunteers: Not accepted

Summary

To evaluate safety, efficacy and pharmacokinetics of palivizumab in children at the age of 24 months or less with immunocompromised medical conditions.

Conditions

• Respiratory Syncytial Virus Infection

Interventions

Type	Name	Description
DRUG	Palivizumab

Timeline

• Start date: 2011-08-01
• Primary completion: 2012-04-01
• Completion: 2012-04-01
• First posted: 2011-11-07
• Last updated: 2013-06-17
• Results posted: 2013-06-17

Locations

6 sites across 1 country: Japan